SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-20-294731
Filing Date
2020-11-16
Accepted
2020-11-16 16:01:13
Documents
31
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d35890d10q.htm 10-Q 822711
2 EX-31.1 d35890dex311.htm EX-31.1 10514
3 EX-31.2 d35890dex312.htm EX-31.2 10523
4 EX-32.1 d35890dex321.htm EX-32.1 4489
5 EX-32.2 d35890dex322.htm EX-32.2 4483
  Complete submission text file 0001193125-20-294731.txt   1985113

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT ayla-20200930.xml EX-101.INS 153906
7 XBRL TAXONOMY EXTENSION SCHEMA ayla-20200930.xsd EX-101.SCH 14379
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ayla-20200930_cal.xml EX-101.CAL 22277
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ayla-20200930_def.xml EX-101.DEF 85448
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE ayla-20200930_lab.xml EX-101.LAB 149684
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ayla-20200930_pre.xml EX-101.PRE 116269
Mailing Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801
Business Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801 (857) 444-0553
Ayala Pharmaceuticals, Inc. (Filer) CIK: 0001797336 (see all company filings)

IRS No.: 823578375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39279 | Film No.: 201316555
SIC: 2836 Biological Products, (No Diagnostic Substances)